<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genetic causes of low LDL-cholesterol&lt;sup&gt;[1-6]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genetic causes of low LDL-cholesterol<sup>[1-6]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Genetic causes of low LDL-cholesterol<sup>[1-6]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic mutation/<br/> inheritance</td> <td class="subtitle1">Functional significance</td> <td class="subtitle1">Prevalence</td> <td class="subtitle1">Laboratory features</td> <td class="subtitle1">LDL-C level</td> <td class="subtitle1">Sequelae</td> <td class="subtitle1">Treatment</td> </tr> <tr> <td>Abetalipoproteinemia</td> <td>Mutation in the microsomal transfer protein, autosomal recessive inheritance</td> <td>Microsomal transfer protein is responsible for the intracellular assembly of apoB and lipids in the liver and intestine</td> <td>&lt;1 in 1,000,000</td> <td>Absent LDL and VLDL (no apoB-containing lipoproteins), triglycerides &lt;30 mg/dL</td> <td> <p>Not detectable to <span class="nowrap_whitespace">20 mg/dL<sup>[1]</sup></span></p> HDL-C <span class="nowrap_whitespace">30 mg/dL<sup>[1]</sup></span></td> <td>Steatorrhea in infancy, failure to thrive, acanthosis, retinitis pigmentosa</td> <td>Fat soluble vitamin supplementation (A, D, E, K)</td> </tr> <tr> <td>Chylomicron retention disease (Anderson disease)</td> <td>Autosomal recessive mutation of <em>Sar1b</em></td> <td><em>Sar1b</em> mutation disrupts protein transport from the endoplasmic reticulum to the Golgi in enterocytes</td> <td>1 in 20,000 to 25,000 births</td> <td> <p>Low LDL-C and HDL-C, elevated creatinine kinase</p> Absence of chylomicrons and apoB-48 post-prandially</td> <td> <p>27 mg/dL ± 15 mg/dL</p> HDL-C 18 ± <span class="nowrap_whitespace">3 mg/dL<sup>[2]</sup></span></td> <td>Infancy with failure to thrive and steatorrhea, abdominal distension, and vomiting. Deficiency of vitamin E and other fat-soluble vitamins, which may have neurological consequences (eg, retinopathy, hypo- or areflexia, myopathy), hepatic steatosis.</td> <td>Removal of long chain fatty acids from the diet, nutritional support, and supplements of fat-soluble vitamins</td> </tr> <tr> <td>Homozygous familial hypobetalipoproteinemia</td> <td>Autosomal recessive inheritance of <em>APOB</em> truncation variant (this results from insertion of a premature stop codon)</td> <td> <p>Interference with the full-length translation of the apoB molecule. This causes a truncated apoB molecule.*</p> Shorter truncations of apoB, which interfere more severely with hepatic secretion of both VLDL-containing mutant apoB and apoB-100.</td> <td> </td> <td>Absent to low LDL, depending on how short the truncated gene is. Low to absent triglycerides, low <span class="nowrap_whitespace">HDL<sup>[3]</sup>.</span></td> <td>Not detectable</td> <td>With short truncations of apoB-impaired chylomicron secretion and steatorrhea at birth. In milder forms, acanthosis may be seen but nothing else.</td> <td> </td> </tr> <tr> <td>Heterozygous familial hypobetalipoproteinemia</td> <td>Mutation of <em>APOB</em> results from insertion of a premature stop codon</td> <td>Interference with the full-length translation of the apoB molecule. This causes a truncated apoB molecule.</td> <td>1 in 10,000</td> <td>Low LDL-C</td> <td>21 ± <span class="nowrap_whitespace">6 (mg/dL)<sup>[4]</sup></span></td> <td>Protective for ASCVD; nonalcoholic fatty liver disease is present in an unknown percentage of individuals</td> <td>Monitor for nonalcoholic fatty liver disease</td> </tr> <tr> <td>Loss-of-function mutations of <em>PCSK9</em></td> <td>Various mutations in <em>PCSK9</em> gene</td> <td>Decreased degradation of the LDL receptor</td> <td>2 to 3%</td> <td>LDL-C is 15 to 28% reduced in heterozygotes. Lower LDL-C seen in compound heterozygotes.</td> <td> <p>Heterozygotes <span class="nowrap_whitespace">110 mg/dL<sup>[5]</sup></span></p> Homozygotes <span class="nowrap_whitespace">15 mg/dL<sup>[5]</sup></span></td> <td>Reduced ASCVD risk</td> <td> </td> </tr> <tr> <td>Familial combined hypolipidemia</td> <td>Loss-of-function mutations in angiopoietin-like protein 3</td> <td>Increased activity of lipoprotein lipase and endothelial lipase (enzymes that break down triglycerides)</td> <td>Not reported<sup>¶</sup></td> <td>Reduced levels of all plasma lipoproteins except lipoprotein(a)</td> <td>19 to 54 mg/dL</td> <td>Heterozygotes; no fatty liver disease. Homozygotes; no diabetes or ASCVD.</td> <td> </td> </tr> <tr> <td>Variant <em>ASGR1</em></td> <td>Loss-of-function variants of a subunit of the <em>ASGR1</em>, heterozygous</td> <td>The hepatic carbohydrate-recognizing <em>ASGR1</em> mediates the endocytosis/lysosomal degradation of desialylated glycoproteins following binding to terminal galactose/N-acetylgalactosamine</td> <td>Not reported</td> <td>Non-HDL-C (in most persons this is LDL-C) is 15 mg/dL lower than in persons without genetic variant</td> <td>92 (wide range, <span class="nowrap_whitespace">IQR 19-170)<sup>[6]</sup></span></td> <td>Protective for ASCVD</td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>LDL: low-density lipoprotein; VLDL: very low-density lipoprotein; apoB: apolipoprotein b; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; ASCVD: atherosclerotic cardiovascular disease; ASGR1: asialoglycoprotein receptor.</p>
<p>* Adopting similar terminology to that used for apoB-100 (normally produced in the liver) and apoB-48 (normally produced by the gut), a wide range of apoB variants have been described to be associated with low-circulating LDL-C, ranging from apoB2 to apoB 89.1. Truncated apoB 27.6 or less is undetectable in the circulation.</p>
¶ 20% of loss with abetalipoproteinemia.</div><div class="graphic_reference">References:
<ol>
<li>Rodríguez Gutiérrez PG, González García JR, Castillo De León YA, et al. A novel p.Gly417Valfs*12 mutation in the MTTP gene causing abetalipoproteinemia: Presentation of the first patient in Mexico and analysis of the previously reported cases. J Clin Lab Anal 2021; 35:e23672.</li>
<li>Peretti N, Sassolas A, Roy CC, et al. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. Orphanet J Rare Dis 2010; 5:24.</li>
<li>Takahashi M, Okazaki H, Ohashi K, et al. Current diagnosis and management of abetalipoproteinemia. J Atheroscler Thromb 2021; 28:1009.</li>
<li>Welty FK, Lichtenstein AH, Barrett PH, et al. Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes. Arterioscler Thromb Vasc Biol 1997; 17:881.</li>
<li>Shapiro MD, Feingold KR, Anawalt B, et al. Monogenic disorders causing hypobetalipoproteinemia. Endotext 2021.</li>
<li>Minicocci I, Santini S, Cantisani V, Stitziel N, et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res 2013; 54:3481.</li>
</ol></div><div id="graphicVersion">Graphic 138697 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
